Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record.

Whole-body FDG-PET imaging in the management of patients with cancer

Hustinx, Roland, Bénard, François, Alavi, Abass·2002·Seminars in Nuclear Medicine

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/snuc.2002.29272

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 136

  1. Gambhir, 1998, Analytical decision model for the cost-effective management of solitary pulmonary nodules, J Clin Oncol, 16, 2113, 10.1200/JCO.1998.16.6.2113 · doi:10.1200/jco.1998.16.6.2113
  2. Gould, 2001, Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis, JAMA, 285, 914, 10.1001/jama.285.7.914 · DOI · Paper page
  3. Dewan, 1995, PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis, Chest, 108, 441, 10.1378/chest.108.2.441 · DOI
  4. Dwamena, 1999, Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s—meta-analytic comparison of PET and CT, Radiology, 213, 530, 10.1148/radiology.213.2.r99nv46530 · DOI · Paper page
  5. Weng, 2000, Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer, Am J Clin Oncol, 23, 47, 10.1097/00000421-200002000-00014 · doi:10.1097/00000421-200002000-00014
  6. Vansteenkiste, 1998, FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localization of regional lymph node metastases? The Leuven Lung Cancer Group, Eur J Nucl Med, 25, 1495, 10.1007/s002590050327 · DOI · Paper page
  7. Gupta, 2000, Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions, Chest, 117, 773, 10.1378/chest.117.3.773 · doi:10.1378/chest.117.3.773
  8. Bury, 1998, Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer, Eur J Nucl Med, 25, 1244, 10.1007/s002590050291 · DOI · Paper page
  9. Erasmus, 1997, Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography, AJR Am J Roentgenol, 168, 1357, 10.2214/ajr.168.5.9129444 · DOI · Paper page
  10. Hustinx, 1998, Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases, Ann Oncol, 9, 397, 10.1023/A:1008290027419 · DOI
  11. Lewis, 1994, Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer, Lancet, 344, 1265, 10.1016/S0140-6736(94)90753-6 · DOI
  12. Weder, 1998, Detection of extrathoracic metastases by positron emission tomography in lung cancer, Ann Thorac Surg, 66, 886, 10.1016/S0003-4975(98)00675-4 · DOI · Paper page
  13. Marom, 1999, Staging non-small cell lung cancer with whole-body PET, Radiology, 212, 803, 10.1148/radiology.212.3.r99se21803 · DOI · Paper page
  14. Saunders, 1999, Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer, Ann Thorac Surg, 67, 790, 10.1016/S0003-4975(98)01257-0 · DOI · Paper page
  15. Vansteenkiste, 1997, Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: A prospective analysis of 50 cases. Leuven Lung Cancer Group, Chest, 112, 1480, 10.1378/chest.112.6.1480 · DOI
  16. Hicks, 2001, Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) provides high impact and powerful prognostic stratification in staging new diagnosed non-small cell lung cancer, J Nucl Med, 42, 1596
  17. Hicks, 2001, The utility of F-18 FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification, J Nucl Med, 42, 1605
  18. Gambhir, 1996, Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma, J Nucl Med, 37, 1428
  19. Scott, 1998, Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis, Ann Thorac Surg, 66, 1876, 10.1016/S0003-4975(98)01055-8 · doi:10.1016/s0003-4975(98)01055-8
  20. Kosuda, 2000, Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan, Chest, 117, 346, 10.1378/chest.117.2.346 · doi:10.1378/chest.117.2.346
  21. Dietlein, 2000, Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: Priority for a PET-based strategy after nodal-negative CT results, Eur J Nucl Med, 27, 1598, 10.1007/s002590000376 · doi:10.1007/s002590000376
  22. Pieterman, 2000, Preoperative staging of non-small-cell lung cancer with positron-emission tomography, N Engl J Med, 343, 254, 10.1056/NEJM200007273430404 · DOI · Paper page
  23. Farrell, 2000, Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease, Radiology, 215, 886, 10.1148/radiology.215.3.r00jn29886 · doi:10.1148/radiology.215.3.r00jn29886
  24. Patz, 2000, Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer, AJR Am J Roentgenol, 174, 769, 10.2214/ajr.174.3.1740769 · doi:10.2214/ajr.174.3.1740769
  25. Hueltenschmidt, 2001, Whole body positron emission tomography in the treatment of Hodgkin disease, Cancer, 91, 302, 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4 · doi:10.1002/1097-0142(20010115)91:2<302::aid-cncr1002>3.0.co;2-4
  26. Buchmann, 2001, 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial, Cancer, 91, 889, 10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5 · DOI · Paper page
  27. Moog, 1997, Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging, Radiology, 203, 795, 10.1148/radiology.203.3.9169707 · DOI · Paper page
  28. Moog, 1998, Extranodal malignant lymphoma: Detection with FDG PET versus CT, Radiology, 206, 475, 10.1148/radiology.206.2.9457202 · DOI · Paper page
  29. Bangerter, 1998, Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease, Ann Oncol, 9, 1117, 10.1023/A:1008486928190 · DOI · Paper page
  30. Jerusalem, 1999, Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma, Nucl Med Commun, 20, 13, 10.1097/00006231-199901000-00004 · DOI
  31. Klose, 2000, Primary staging of lymphomas: Cost-effectiveness of FDG-PET versus computed tomography, Eur J Nucl Med, 27, 1457, 10.1007/s002590000323 · doi:10.1007/s002590000323
  32. Moog, 1998, 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow, J Clin Oncol, 16, 603, 10.1200/JCO.1998.16.2.603 · DOI · Paper page
  33. Carr, 1998, Detection of lymphoma in bone marrow by whole-body positron emission tomography, Blood, 91, 3340, 10.1182/blood.V91.9.3340 · DOI · Paper page
  34. Najjar, 2001, Positron emission tomography for staging low-grade non Hodgkin's lymphomas, Cancer Biother Radiopharm, 16, 297, 10.1089/108497801753131372 · DOI
  35. Shah, 2000, The impact of FDG positron emission tomography imaging on the management of lymphomas, Br J Radiol, 73, 482, 10.1259/bjr.73.869.10884743 · DOI
  36. Zinzani, 1999, The role of positron emission tomography (PET) in the management of lymphoma patients, Ann Oncol, 10, 1181, 10.1023/A:1008327127033 · DOI · Paper page
  37. Jerusalem, 1999, Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging, Blood, 94, 429, 10.1182/blood.V94.2.429 · DOI · Paper page
  38. Spaepen, 2001, Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?, J Clin Oncol, 19, 414, 10.1200/JCO.2001.19.2.414 · DOI · Paper page
  39. Cremerius, 1998, Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma, Nucl Med Commun, 19, 1055, 10.1097/00006231-199811000-00005 · DOI
  40. de Wit, 1997, Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma, Ann Oncol, 8, 57, 10.1093/annonc/8.suppl_1.S57 · DOI · Paper page
  41. Mikhaeel, 2000, 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas, Ann Oncol, 11, 147, 10.1093/annonc/11.suppl_1.S147 · DOI
  42. Romer, 1998, Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose, Blood, 91, 4464
  43. Jerusalem, 2000, Persistent tumor 18f-fdg uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma, Haematologica, 85, 613
  44. Kostakoglu, 2000, Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?, Eur J Nucl Med, 27, 1564, 10.1007/s002590000340 · doi:10.1007/s002590000340
  45. Huebner, 2000, A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer, J Nucl Med, 41, 1177
  46. Staib, 2000, Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?, Am J Surg, 180, 1, 10.1016/S0002-9610(00)00406-2 · DOI
  47. Whiteford, 2000, Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum, Dis Colon Rectum, 43, 759, 10.1007/BF02238010 · DOI · Paper page
  48. Meta, 2001, Impact of (18)f-fdg pet on managing patients with colorectal cancer: The referring physician's perspective, J Nucl Med, 42, 586
  49. Fong, 1997, Liver resection for colorectal metastases, J Clin Oncol, 15, 938, 10.1200/JCO.1997.15.3.938 · DOI · Paper page
  50. Jarnagin, 1999, Liver resection for metastatic colorectal cancer: Assessing the risk of occult irresectable disease, J Am Coll Surg, 188, 33, 10.1016/S1072-7515(98)00272-5 · DOI
  51. Vitola, 1996, Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver, Am J Surg, 171, 21, 10.1016/S0002-9610(99)80067-1 · DOI · Paper page
  52. Lai, 1996, The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver, Arch Surg, 131, 703, 10.1001/archsurg.1996.01430190025007 · DOI · Paper page
  53. Fong, 1999, Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases, Am J Surg, 178, 282, 10.1016/S0002-9610(99)00187-7 · DOI · Paper page
  54. Strasberg, 2001, Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study, Ann Surg, 233, 293, 10.1097/00000658-200103000-00001 · DOI · Paper page
  55. Brennan, 2001, PET scanning in malignancy: Infant, adolescent or mature citizen?, Ann Surg, 233, 320, 10.1097/00000658-200103000-00004 · DOI
  56. Park, 2001, Decision analysis for the cost-effective management of recurrent colorectal cancer, Ann Surg, 233, 310, 10.1097/00000658-200103000-00003 · DOI
  57. Flanagan, 1998, Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer, Ann Surg, 227, 319, 10.1097/00000658-199803000-00001 · DOI · Paper page
  58. Flamen, 2001, Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer. The utility of positron emission tomography (PET), Eur J Cancer, 37, 862, 10.1016/S0959-8049(01)00049-1 · doi:10.1016/s0959-8049(01)00049-1
  59. Block, 1997, Improvement in staging of esophageal cancer with the addition of positron emission tomography, Ann Thorac Surg, 64, 770, 10.1016/S0003-4975(97)00619-X · DOI · Paper page
  60. Meltzer, 2000, Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography, Clin Nucl Med, 25, 882, 10.1097/00003072-200011000-00005 · DOI
  61. Luketich, 1997, Role of positron emission tomography in staging esophageal cancer, Ann Thorac Surg, 64, 765, 10.1016/S0003-4975(97)00624-3 · DOI · Paper page
  62. Rankin, 1998, Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma, Clin Radiol, 53, 659, 10.1016/S0009-9260(98)80292-4 · DOI
  63. Flanagan, 1997, Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography, AJR Am J Roentgenol, 168, 417, 10.2214/ajr.168.2.9016218 · DOI · Paper page
  64. Flamen, 2000, Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma, J Clin Oncol, 18, 3202, 10.1200/JCO.2000.18.18.3202 · DOI · Paper page
  65. Brucher, 2001, Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography, Ann Surg, 233, 300, 10.1097/00000658-200103000-00002 · DOI · Paper page
  66. Flamen, 2000, The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer, J Thorac Cardiovasc Surg, 120, 1085, 10.1067/mtc.2000.110464 · DOI · Paper page
  67. Stollfuss, 1995, 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation, Radiology, 195, 339, 10.1148/radiology.195.2.7724750 · DOI
  68. Inokuma, 1995, Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US, Radiology, 195, 345, 10.1148/radiology.195.2.7724751 · DOI · Paper page
  69. Imdahl, 1999, Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer, Br J Surg, 86, 194, 10.1046/j.1365-2168.1999.01016.x · DOI
  70. Delbeke, 1999, Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma, J Nucl Med, 40, 1784
  71. Sendler, 2000, Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: Diagnostic limitations, World J Surg, 24, 1121, 10.1007/s002680010182 · DOI
  72. Shreve, 1998, Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease, Eur J Nucl Med, 25, 259, 10.1007/s002590050226 · DOI · Paper page
  73. Diederichs, 2000, Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses, Pancreas, 20, 109, 10.1097/00006676-200003000-00001 · DOI · Paper page
  74. Frohlich, 1999, Detection of liver metastases from pancreatic cancer using FDG PET, J Nucl Med, 40, 250
  75. Nakamoto, 1999, Contribution of PET in the detection of liver metastases from pancreatic tumours, Clin Radiol, 54, 248, 10.1016/S0009-9260(99)91160-1 · DOI
  76. Rose, 1999, 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer, Ann Surg, 229, 729, 10.1097/00000658-199905000-00016 · DOI · Paper page
  77. Maisey, 2000, FDG-PET in the prediction of survival of patients with cancer of the pancreas: A pilot study, Br J Cancer, 83, 287, 10.1054/bjoc.2000.1166 · DOI
  78. Higashi, 1999, Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET, J Nucl Med, 40, 1424
  79. Mijnhout, 2001, Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients, Cancer, 91, 1530, 10.1002/1097-0142(20010415)91:8<1530::AID-CNCR1162>3.0.CO;2-# · doi:10.1002/1097-0142(20010415)91:8<1530::aid-cncr1162>3.0.co;2-#
  80. Schwimmer, 2000, A review of the literature for whole-body FDG PET in the management of patients with melanoma, Quart J Nucl Med, 44, 153
  81. Acland, 2001, Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma, J Clin Oncol, 19, 2674, 10.1200/JCO.2001.19.10.2674 · doi:10.1200/jco.2001.19.10.2674
  82. Wagner, 1999, Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy, J Clin Oncol, 17, 1508, 10.1200/JCO.1999.17.5.1508 · DOI · Paper page
  83. Damian, 1996, Positron emission tomography in the detection and management of metastatic melanoma, Melanoma Res, 6, 325, 10.1097/00008390-199608000-00008 · DOI
  84. Jadvar, 2000, The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma, Clin Nucl Med, 25, 48, 10.1097/00003072-200001000-00011 · DOI
  85. Tyler, 2000, Positron emission tomography scanning in malignant melanoma, Cancer, 89, 1019, 10.1002/1097-0142(20000901)89:5<1019::AID-CNCR11>3.0.CO;2-0 · doi:10.1002/1097-0142(20000901)89:5<1019::aid-cncr11>3.0.co;2-0
  86. Rinne, 1998, Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients, Cancer, 82, 1664, 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2 · DOI · Paper page
  87. Rege, 1994, Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers, Cancer, 73, 3047, 10.1002/1097-0142(19940615)73:12<3047::AID-CNCR2820731225>3.0.CO;2-# · doi:10.1002/1097-0142(19940615)73:12<3047::aid-cncr2820731225>3.0.co;2-#
  88. Myers, 1998, Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer, J Otolaryngol, 27, 342
  89. Adams, 1998, Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer, Eur J Nucl Med, 25, 1255, 10.1007/s002590050293 · DOI · Paper page
  90. McGuirt, 1995, A comparative diagnostic study of head and neck nodal metastases using positron emission tomography, Laryngoscope, 105, 373, 10.1288/00005537-199504000-00006 · DOI
  91. Braams, 1995, Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI, J Nucl Med, 36, 211
  92. Benchao, 1996, The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer, Acta Otolaryngol (Stockh), 116, 332, 10.3109/00016489609137852 · DOI
  93. Kresnik, 2001, Evaluation of head and neck cancer with 18F-FDG PET: A comparison with conventional methods, Eur J Nucl Med, 28, 816, 10.1007/s002590100554 · DOI · Paper page
  94. Greven, 1997, Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer?, Can J Sci Am, 3, 353
  95. Anzai, 1996, Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses, Radiology, 200, 135, 10.1148/radiology.200.1.8657901 · DOI · Paper page
  96. Lapela, 1995, Head and neck cancer: Detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose, Radiology, 197, 205, 10.1148/radiology.197.1.7568825 · DOI · Paper page
  97. Lonneux, 2000, Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient, Laryngoscope, 110, 1493, 10.1097/00005537-200009000-00016 · DOI
  98. Farber, 1999, Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography, Laryngoscope, 109, 970, 10.1097/00005537-199906000-00024 · DOI
  99. Li, 2001, Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography, Clin Nucl Med, 26, 131, 10.1097/00003072-200102000-00008 · DOI
  100. Kole, 1998, Detection of unknown occult primary tumors using positron emission tomography, Cancer, 82, 1160, 10.1002/(SICI)1097-0142(19980315)82:6<1160::AID-CNCR22>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19980315)82:6<1160::aid-cncr22>3.0.co;2-3
  101. Lassen, 1999, 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT), Eur J Can, 35, 1076, 10.1016/S0959-8049(99)00077-5 · DOI
  102. Greven, 1999, Occult primary tumors of the head and neck: Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose, Cancer, 86, 114, 10.1002/(SICI)1097-0142(19990701)86:1<114::AID-CNCR16>3.0.CO;2-E · doi:10.1002/(sici)1097-0142(19990701)86:1<114::aid-cncr16>3.0.co;2-e
  103. Aassar, 1999, Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors, Radiology, 210, 177, 10.1148/radiology.210.1.r99ja48177 · DOI
  104. Bohuslavizki, 2000, FDG PET detection of unknown primary tumors, J Nucl Med, 41, 816
  105. Grunwald, 1996, Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer, Eur J Nucl Med, 23, 312, 10.1007/BF00837630 · DOI
  106. Grunwald, 1999, Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study, Eur J Nucl Med, 26, 1547, 10.1007/s002590050493 · DOI · Paper page
  107. Dietlein, 1997, Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer, Eur J Nucl Med, 24, 1342, 10.1007/s002590050158 · DOI · Paper page
  108. Wang, 1999, [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels, J Clin Endocrinol Metab, 84, 2291, 10.1210/jcem.84.7.5827 · doi:10.1210/jcem.84.7.5827 · Paper page
  109. Shiga, 2001, Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma, J Nucl Med, 42, 414
  110. Yeo, 2001, F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes, Head Neck, 23, 94, 10.1002/1097-0347(200102)23:2<94::AID-HED1004>3.0.CO;2-R · doi:10.1002/1097-0347(200102)23:2<94::aid-hed1004>3.0.co;2-r
  111. Altenvoerde, 1998, Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans, Langenbecks Arch Surg, 383, 160, 10.1007/s004230050109 · DOI
  112. Jadvar, 1998, Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography, Nucl Med Commun, 19, 547, 10.1097/00006231-199806000-00006 · DOI
  113. Chung, 1999, Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan, J Nucl Med, 40, 986
  114. Muros, 2000, Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels, Am J Surg, 179, 457, 10.1016/S0002-9610(00)00381-0 · doi:10.1016/s0002-9610(00)00381-0
  115. Alnafisi, 2000, FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma, J Nucl Med, 41, 1010
  116. Schluter, 2001, Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan, J Nucl Med, 42, 71
  117. Adler, 1993, Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET, Radiology, 187, 743, 10.1148/radiology.187.3.8497624 · DOI · Paper page
  118. Noh, 1998, Diagnostic value of positron emission tomography for detecting breast cancer, World J Surg, 22, 223, 10.1007/s002689900374 · DOI
  119. Palmedo, 1997, Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours, Eur J Nucl Med, 24, 1138
  120. Hoh, 1993, Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose, J Comput Assist Tomogr, 17, 582, 10.1097/00004728-199307000-00012 · DOI
  121. Scheidhauer, 1996, Qualitative [18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability, Eur J Nucl Med, 23, 618, 10.1007/BF00834522 · DOI
  122. Avril, 2000, Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations, J Clin Oncol, 18, 3495, 10.1200/JCO.2000.18.20.3495 · DOI · Paper page
  123. Avril, 2001, Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis, J Nucl Med, 42, 9
  124. Crippa, 1998, Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer, J Nucl Med, 39, 4
  125. Smith, 1998, Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose, Ann Surg, 228, 220, 10.1097/00000658-199808000-00012 · DOI
  126. Avril, 1996, Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose, J Natl Cancer Inst, 88, 1204, 10.1093/jnci/88.17.1204 · DOI · Paper page
  127. Bender, 1997, Value of 18fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma, Anticancer Res, 17, 1687
  128. Schirrmeister, 2001, Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures, Eur J Nucl Med, 28, 351, 10.1007/s002590000448 · DOI · Paper page
  129. Schirrmeister, 1999, Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography, J Clin Oncol, 17, 2381, 10.1200/JCO.1999.17.8.2381 · DOI · Paper page
  130. Moon, 1998, Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma, J Nucl Med, 39, 431
  131. Hathaway, 1999, Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience, Radiology, 210, 807, 10.1148/radiology.210.3.r99mr43807 · DOI
  132. Jansson, 1995, Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?, J Clin Oncol, 13, 1470, 10.1200/JCO.1995.13.6.1470 · DOI · Paper page
  133. Wahl, 1993, Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation, J Clin Oncol, 11, 2101, 10.1200/JCO.1993.11.11.2101 · DOI · Paper page
  134. Schelling, 2000, Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer, J Clin Oncol, 18, 1689, 10.1200/JCO.2000.18.8.1689 · DOI · Paper page
  135. Smith, 2000, Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy, J Clin Oncol, 18, 1676, 10.1200/JCO.2000.18.8.1676 · DOI · Paper page
  136. Balk, 2001, PET scans and technology assessment: Deja vu?, JAMA, 285, 936, 10.1001/jama.285.7.936 · DOI

Cited by

See all 199

Metadata

Authors
Hustinx, R., Bénard, F., & Alavi, A.
Venue
Seminars in Nuclear Medicine
Publisher
Elsevier BV
Published
2002-01
Volume
32
Issue
1
Pages
35-46
ISSN
0001-2998 (ISSN-L)
OpenAlex
W2073246902
Cited by
199
References
0
FWCI
16.88
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Whole-body FDG-PET imaging in the management of patients with cancer. https://app.cochat.ai/papers/10.1053/snuc.2002.29272
The paper
Hustinx, R., Bénard, F., & Alavi, A. (2002). Whole-body FDG-PET imaging in the management of patients with cancer. Seminars in Nuclear Medicine. https://doi.org/10.1053/snuc.2002.29272

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.